Compare Gilead Sciences, Inc. (GILD) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tyson Foods, Inc. — how do they compare? Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B), while Tyson Foods, Inc. trades at $53.26 (market cap $18.41B). The key difference: Gilead Sciences, Inc. is far larger — about 9.9× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Tyson Foods, Inc. for 76 Days on average.
| GILD | TSN | |
|---|---|---|
Market Cap | $182.40B | $18.41B |
Volume | 4,469,821 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $68.75 |
52-Week Low | $116.74 | $50.47 |
Typical Hold Time | 111 Days | 76 Days |
Enterprise Value | $205.46B | $25.68B |
Dividend Yield | 2.23% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Tyson Foods (TSN) trades at $52.70, up 1.93% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth remains modest at 1.5%-2.0% for 2026. Analysts maintain a Buy consensus with $65.40 target, but recent news highlights investigations into guidance revisions and beef segment challenges.
Outlook remains cautious with upside potential from execution improvements, but risks include beef segment losses, margin pressure, and ongoing securities investigations. The stock offers value with low P/S of 0.33 and consistent dividends, but requires monitoring of operational turnaround and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
